ArticleAmerican journal of surgery2025
Patients with normocalcemic versus hypercalcemic hyperparathyroidism: What's really the difference?
Article in American journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Incidence of Ectopic Parathyroid Glands in Primary, Secondary, and Tertiary Hyperparathyroidism.The Journal of surgical research · 2026Article
- Future Directions in Hypercalcemic and Normocalcemic Primary Hyperparathyroidism: FRAXplus for 10-Year Fracture Risk Assessment (A Retrospective Study).Life (Basel, Switzerland) · 2026Article
- Article
- Paget's Disease of Bone and Normocalcemic Variant of Primary Hyperparathyroidism in an Osteoporotic Male: Exceptional Coexistence.Reports (MDPI) · 2025Article
- An Updated Perspective of the Clinical Features and Parathyroidectomy Impact in Primary Hyperparathyroidism Amid Multiple Endocrine Neoplasia Type 1 (MEN1): Focus on Bone Health.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionPrimary hyperparathyroidism (HPT) is typically characterized by elevated parathyroid hormone (PTH) and hypercalcemia; however, some patients develop normocalcemic hyperparathyroidism. Patients with normocalcemic HPT have an elevated PTH with normal calcium levels and no other secondary causes of elevated PTH, and therefore have a unique biochemical profile. The aim of this project is to compare the demographics, presentation, and outcomes for patients with normocalcemic HPT versus patients with hypercalcemic HPT undergoing parathyroidectomy.
methodsA single institution, retrospective review was conducted between January 2016 and June 2022. Patients were classified as either having hypercalcemic (calcium >10.4 mg/dL) or normocalcemic (calcium ≤10.4 mg/dL) HPT. Cure was defined as normal calcium for 6 months post-operatively in the hypercalcemic HPT group and normal PTH (<88 pg/mL) for 6 months post-operatively in the normocalcemic HPT group.
resultsOf the 701 patients included in the study, 566 (80.7 %) had hypercalcemic HPT and 135 (19.3 %) had normocalcemic HPT. The preoperative Ca was 11 ± 0.7 mg/dL in the hypercalcemic group and 9.8 ± 0.4 mg/dL in the normocalcemic group (p < 0.001). The preoperative PTH was 148.2 ± 180 pg/dL in the hypercalcemic group and 117.4 ± 105.3 pg/dL in the normocalcemic group (p = 0.06). The average age of normocalcemic patients was 56 ± 15 years, compared to 59 ± 15 years in the hypercalcemic group (p = 0.07). There was no significant difference in sex (p = 0.42). African American patients were more likely to present with hypercalcemic HPT (19.1 %) than with normocalcemic HPT (9.6 %, p = 0.01). Normocalcemic patients were more likely to report pre-operative symptoms of kidney stones compared to patients with hypercalcemia (53.3 % versus 30.4 %, p < 0.001). There was no significant difference in pre-operative symptoms of fatigue, bone pain, or fractures. Patients with hypercalcemic HPT were more likely to present with adenoma (64.3 %); whereas patients with normocalcemic HPT were more likely to present with hyperplasia (43.3 %, p < 0.001). More patients with normocalcemic HPT underwent thymectomy compared to patients with hypercalcemia (39.3 % versus 20.8 % respectively, p < 0.001). 92.0 % of normocalcemic patients achieved cure post-operatively, which was significantly less than in the hypercalcemic group (97.0 %, p = 0.02). The 8.0 % of normocalcemic patients that did not achieve cure had a mean PTH level of 147.9 ± 159 pg/mL at 6 months post-operative. Four patients with normocalcemic HPT had recurrence of disease (3 %), and three of the four patients underwent bilateral exploration.
conclusionsPatients with normocalcemic HPT present with different symptoms compared to patients with hypercalcemic HPT prior to surgery. Additionally, patients with normocalcemic HPT are less likely to achieve cure after surgery, which warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.